{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:58:24Z","timestamp":1790387904504,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endometrial carcinoma (EC) is a leading gynecological malignancy predominantly driven by hormonal imbalances. While the roles of estrogen and progesterone are well established, the influence of androgenic signaling, specifically through the androgen receptor, remains an underexplored diagnostic dimension. This study aims to evaluate the immunohistochemical (IHC) expression of the androgen receptor (AR) in EC tissue samples and correlate its presence with key clinicopathological parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study was conducted utilizing 40 formalin-fixed, paraffin-embedded (FFPE) tissue specimens from patients diagnosed with EC who had undergone total hysterectomies. Cases were histologically categorized according to World Health Organization (WHO) criteria into endometrioid endometrial carcinoma (EEC),\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200932 and serous endometrial carcinoma,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098, and classified by the International Federation of Gynecology and Obstetrics (FIGO) for staging and grading. IHC staining was performed to evaluate nuclear AR expression, defined as positive when &gt;\u200910% of neoplastic cells exhibited distinct nuclear staining. Data were statistically analyzed to identify associations between AR status and patient age, histological subtype, tumor grade, and stage.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Distinct nuclear AR positivity was observed in 50% (20 of 40) of the total cohort. Expression was exclusively restricted to EEC (62.5% positive), whereas all serous carcinomas lacked expression entirely (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002). Notably, positive receptor expression demonstrated a strong inverse relationship with advanced FIGO stage and high tumor grade. Immunoreactivity was significantly enriched in early-stage disease (62.1% in Stages I and II versus 18.2% in Stage III;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.013) and low-grade tumors (76.0% in Grades 1 and 2 versus 6.7% in Grade 3;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Patient age at diagnosis yielded no statistically significant correlation with expression status (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.206).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The AR is frequently expressed in low-grade, early-stage EEC, suggesting that AR may be associated with well-differentiated tumors and favorable clinicopathological parameters. The integration of AR immunohistochemistry into routine pathology panels could serve as a hypothesis-generating foundation for future clinical trials investigating targeted antiandrogen therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13000-026-01848-x","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:44:36Z","timestamp":1790383476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunohistochemical evaluation of androgen receptor expression in endometrial carcinoma and its clinicopathological significance"],"prefix":"10.1186","volume":"21","author":[{"given":"Alaa saad Abd elhamid","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba Ashraf","family":"Hosni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram Salaheldeen","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzahraa Abdelmoktader","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"1","key":"1848_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1848_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1848_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2016.12.010","volume":"144","author":"AA Suarez","year":"2017","unstructured":"Suarez AA, Felix AS, Cohn DE. Bokhman Redux: Endometrial cancer types in the 21st century. Gynecol Oncol. 2017;144(2):243\u20139.","journal-title":"Gynecol Oncol"},{"issue":"7447","key":"1848_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"G Getz","year":"2013","unstructured":"Getz G, Gabriel SB, Cibulskis K, Lander E, Sivachenko A, Sougnez C, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67\u201373.","journal-title":"Nature"},{"key":"1848_CR5","unstructured":"Herrington CS, Board WC. of TE. Female Genital Tumours. WHO Female Genital Tumours. 2020. 632 p."},{"issue":"2","key":"1848_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.14923","volume":"162","author":"JS Berek","year":"2023","unstructured":"Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. Int J Gynecol Obstet. 2023;162(2):383\u201394.","journal-title":"Int J Gynecol Obstet"},{"key":"1848_CR7","doi-asserted-by":"crossref","unstructured":"Dobrzycka B, Terlikowska KM, Kowalczuk O, Niklinski J, Kinalski M, Terlikowski SJ. Prognosis of Stage I Endometrial Cancer According to the FIGO 2023 Classification Taking into Account Molecular Changes. Cancers (Basel). 2024;16(2).","DOI":"10.3390\/cancers16020390"},{"key":"1848_CR8","doi-asserted-by":"crossref","unstructured":"Lv M, Yu J, Huang Y, Ma J, Xiang J, Wang Y et al. Androgen Signaling in Uterine Diseases: New Insights and New Targets. Biomolecules. 2022;12(11).","DOI":"10.3390\/biom12111624"},{"issue":"2","key":"1848_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41591-020-0751-5","volume":"26","author":"KS Ruth","year":"2020","unstructured":"Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, et al. Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med. 2020;26(2):252\u20138.","journal-title":"Nat Med"},{"issue":"9","key":"1848_CR10","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/s41416-021-01518-3","volume":"125","author":"A Mullee","year":"2021","unstructured":"Mullee A, Dimou N, Allen N, O\u2019Mara T, Gunter MJ, Murphy N. Testosterone, sex hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk: observational and Mendelian randomization analyses. Br J Cancer. 2021;125(9):1308\u201317.","journal-title":"Br J Cancer"},{"issue":"9","key":"1848_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.tem.2022.06.001","volume":"33","author":"M Gjorgoska","year":"2022","unstructured":"Gjorgoska M, Rizner TL. Integration of androgen hormones in endometrial cancer biology. Trends Endocrinol Metab. 2022;33(9):639\u201351.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"1848_CR12","first-page":"740","volume":"7","author":"K Kayahashi","year":"2024","unstructured":"Kayahashi K, Hasan M, Khatun A, Kohno S, Terakawa J, Horike SI, et al. Androgen-responsive FOXP4 is a target for endometrial carcinoma. Commun Biol 2024 71. 2024;7(1):740.","journal-title":"Commun Biol 2024 71"},{"key":"1848_CR13","doi-asserted-by":"crossref","unstructured":"Ma\u010dek P, Molinari N, Sobo\u010dan M, Knez J. What Role do Androgens Play in Endometrial Cancer? J Pers Med 2023, 13,. 2023;13(2).","DOI":"10.3390\/jpm13020341"},{"issue":"2","key":"1848_CR14","first-page":"310","volume":"27","author":"TE Hickey","year":"2021","unstructured":"Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, et al. The androgen receptor is a tumor suppressor in estrogen receptor\u2013positive breast cancer. Nat Med 2021 272. 2021;27(2):310\u201320.","journal-title":"Nat Med 2021 272"},{"issue":"5","key":"1848_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/PGP.0000000000000355","volume":"36","author":"Z Mahdi","year":"2017","unstructured":"Mahdi Z, Abdulfatah E, Pardeshi V, Hassan O, Schultz D, Morris R, et al. The impact of androgen receptor expression on endometrial carcinoma recurrence and survival. Int J Gynecol Pathol. 2017;36(5):405\u201311.","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"1848_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/PGP.0000000000000401","volume":"37","author":"SL Zadeh","year":"2018","unstructured":"Zadeh SL, Duska LR, Mills AM. Androgen Receptor Expression in Endometrial Carcinoma. Int J Gynecol Pathol. 2018;37(2):167\u201373.","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"1848_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40944-023-00727-3","volume":"21","author":"S Masoodi","year":"2023","unstructured":"Masoodi S, Wahid MA, Yasin SB, Qazi D, Banday I, Faizaan, et al. Androgen Receptor Expression in Endometrial Carcinoma and its Correlation with Clinicopathological Features-An Experience at a Tertiary Care Hospital in North India. Indian J Gynecol Oncol 2023 212. 2023;21(2):49\u2013.","journal-title":"Indian J Gynecol Oncol 2023 212"},{"key":"1848_CR18","doi-asserted-by":"crossref","unstructured":"Viehweger F, Hoop J, Tinger LM, Bernreuther C, B\u00fcscheck F, Clauditz TS et al. Frequency of Androgen Receptor Positivity in Tumors: A Study Evaluating More Than 18,000 Tumors. Biomed 2024, Vol 12,. 2024;12(5).","DOI":"10.3390\/biomedicines12050957"},{"issue":"1","key":"1848_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-018-3403-9","volume":"11","author":"AA Hashmi","year":"2018","unstructured":"Hashmi AA, Hussain ZF, Qadri A, Irfan M, Ramzan S, Faridi N, et al. Androgen receptor expression in endometrial carcinoma and its correlation with clinicopathologic features. BMC Res Notes. 2018;11(1):1\u20135.","journal-title":"BMC Res Notes"},{"issue":"9 September","key":"1848_CR20","first-page":"1","volume":"18","author":"NA Moatamed","year":"2023","unstructured":"Moatamed NA, Vahdatshariatpanahi S, Gjertson DW, Sachs CR, Kang Y, Ostrzega N, et al. Androgen receptor and its correlation with estrogen and progesterone receptors, aimed for identification of cases for future antiandrogen therapy in endometrial cancers. PLoS ONE. 2023;18(9 September):1\u201318.","journal-title":"PLoS ONE"},{"issue":"June","key":"1848_CR21","first-page":"1","volume":"12","author":"X Wu","year":"2022","unstructured":"Wu X, Zhong X, Huo X, Zhang J, Yang X, Zhang Y. The Clinicopathological Significance and Prognostic Value of Androgen Receptor in Endometrial Carcinoma: A Meta-Analysis. Front Oncol. 2022;12(June):1\u20137.","journal-title":"Front Oncol"},{"issue":"31","key":"1848_CR22","doi-asserted-by":"publisher","first-page":"49289","DOI":"10.18632\/oncotarget.10334","volume":"7","author":"IL Tangen","year":"2016","unstructured":"Tangen IL, Onyango TB, Kopperud R, Berg A, Halle MK, \u00d8yan AM, et al. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget. 2016;7(31):49289\u201398.","journal-title":"Oncotarget"},{"issue":"1","key":"1848_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/PGP.0000000000000756","volume":"41","author":"J Cao","year":"2022","unstructured":"Cao J, Hacking S, Chavarria-Bernal HD, Bhuiya TA, Khutti S. Androgen Receptor Immunohistochemical Expression in Undifferentiated\/Dedifferentiated Endometrial Carcinoma. Int J Gynecol Pathol. 2022;41(1):28\u201334.","journal-title":"Int J Gynecol Pathol"},{"issue":"January","key":"1848_CR24","doi-asserted-by":"publisher","first-page":"155922","DOI":"10.1016\/j.prp.2025.155922","volume":"269","author":"M Paudice","year":"2025","unstructured":"Paudice M, Greppi M, Valle L, Piol N, Barra F, Mammoliti S, et al. The role of the Androgen Receptor (AR) in endometrial cancer aggressiveness: Correlation with other prognostic markers and therapeutic implications. A retrospective observational study. Pathol Res Pract. 2025;269(January):155922.","journal-title":"Pathol Res Pract"},{"issue":"6","key":"1848_CR25","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/bjc.2016.16","volume":"114","author":"AM Kamal","year":"2016","unstructured":"Kamal AM, Bulmer JN, Decruze SB, Stringfellow HF, Martin-Hirsch P, Hapangama DK. Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival. Br J Cancer. 2016;114(6):688\u201396.","journal-title":"Br J Cancer"},{"key":"1848_CR26","doi-asserted-by":"crossref","unstructured":"Gibson DA, Simitsidellis I, Collins F, Saunders PTK. Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders. Int J Mol Sci. 2018;19(10).","DOI":"10.3390\/ijms19103276"},{"key":"1848_CR27","doi-asserted-by":"crossref","unstructured":"Lissaman AC, Girling JE, Cree LM, Campbell RE, Ponnampalam AP. Androgen signalling in the ovaries and endometrium. Mol Hum Reprod. 2023;29(6).","DOI":"10.1093\/molehr\/gaad017"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-026-01848-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01848-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-026-01848-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:59:49Z","timestamp":1790384389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13000-026-01848-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1848"],"URL":"https:\/\/doi.org\/10.1186\/s13000-026-01848-x","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and granted formal ethical approval by the Research Ethics Committee at the Faculty of Medicine, Fayoum University. Due to the retrospective nature of the study and the use of anonymized archival tissue, the requirement for direct informed patient consent was waived by the Research Ethics Committee at the Faculty of Medicine, Fayoum University.","order":1,"name":"Ethics","label":"<b>Ethics approval and consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"<b>Consent for publication<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"67"}}